Avisi Technologies to Present Visiplate 2-Year Data - Sep 30

The Story

Avisi Technologies said its VITA trial has completed two-year follow-up in primary open-angle glaucoma patients and will present the long-term VisiPlate® results at the 2026 American Academy of Ophthalmology annual meeting. Dr. Jonathan S. Myers is scheduled to report the data at a poster session, and the company cited outcome metrics including 0%, 42.6% and 46.7% in its release.

Why It Matters For Your Portfolio

• Two-year clinical milestone completed, with cited metrics of 0%, 42.6% and 46.7% — these figures provide inputs you can use in valuation models and risk scenarios.
• Presentation at AAO brings clinical visibility; clinician and partner reaction to the poster could influence commercial prospects and development timelines.
• Company previously announced positive 12-month clinical data, so the 24-month readout will test durability and could materially change clinical adoption assumptions.
• Multiple data points now exist for analysis, which helps quantify upside and downside risk before any regulatory or partnership moves are announced.

The Trade

This is primarily relevant to speculative healthcare and medical-device investors tracking clinical catalysts. Watch the AAO poster session and any subsequent full data release or peer-reviewed publication as the next near-term catalysts. Analysts and investors should monitor reported adverse event rates and durability metrics at 24 months as key risk triggers rather than treating earlier 12-month results as definitive.